Surotomycin
Also known as: CB-064, CB-315, MK-4261, Surotomycin
Source Surotomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Surotomycin is an investigational cyclic lipopeptide antibiotic administered orally for the treatment of Clostridioides difficile infection (CDI). Developed to target C. difficile while sparing the broader gut microbiota, it aims to reduce disease recurrence and preserve microbial diversity in patients with acute CDI.
Mechanism of Action
Surotomycin acts by disrupting the cellular membrane of C. difficile, impairing membrane integrity during both logarithmic and stationary growth phases. This membrane‑targeting activity leads to bacterial death without affecting Gram‑negative anaerobes or facultative anaerobes, contributing to its microbiome‑sparing profile. Its low oral bioavailability ensures high concentrations within the gastrointestinal lumen where the pathogen resides.
What the Research Shows
Preclinical studies demonstrated that surotomycin is well tolerated and effective in hamster models of CDI. A phase‑2 trial reported that 250 mg twice daily reduced recurrence rates compared with vancomycin. Subsequent systematic reviews and meta‑analyses of randomized trials found no statistically significant difference in sustained clinical cure or overall recurrence between surotomycin and vancomycin, though a subgroup analysis showed lower recurrence of the NAP1/BI/027 strain with surotomycin. Overall, evidence is characterized as moderate‑certainty, with no regulatory approval to date.
Reported Benefits
Evidence suggests surotomycin provides targeted activity against C. difficile while minimally disturbing the normal gut flora, potentially limiting dysbiosis‑related recurrence. Phase‑2 data indicated lower recurrence rates versus vancomycin, and a pooled analysis showed a significant reduction in recurrence of the hypervirulent NAP1/BI/027 strain. Its oral formulation delivers high colonic concentrations due to poor systemic absorption, supporting its use as a microbiome‑preserving option.
Limitations of the Evidence
Clinical findings are mixed; meta‑analyses did not demonstrate a significant advantage over vancomycin for overall cure or recurrence. The certainty of evidence is moderate, and larger phase‑III trials are lacking. Surotomycin remains investigational with no approved indication, and its efficacy against diverse C. difficile strains beyond NAP1/BI/027 is not fully established.
Safety Considerations
Phase‑2 studies reported that surotomycin was well tolerated, with no major safety signals identified in the trials. Specific adverse‑event profiles were not detailed in the abstracts, but the drug’s low systemic absorption suggests a limited risk of systemic toxicity. Ongoing monitoring for gastrointestinal side effects and potential interactions remains warranted.
How It Is Administered
Surotomycin is administered orally, typically as a 250 mg tablet taken twice daily for a 10‑day course in clinical studies. Its formulation results in low oral bioavailability, allowing high concentrations to remain in the gastrointestinal tract where C. difficile resides.
Routes of Administration
Goals & Uses
- Prevention of CDI recurrenceAnti InfectiveModerate
- Clostridioides difficile infectionInfectionModerate
- Treatment of Clostridioides difficile infectionAntimicrobialModerate
Contraindications
- Known hypersensitivity to surotomycin or related lipopeptidesAllergyHigh
- Hypersensitivity to surotomycin or related lipodepsipeptidesAllergyHigh
Adverse Effects
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Diarrhea (non‑C. difficile)GastrointestinalCommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
- Abdominal painGastrointestinalCommonPain or discomfort in the abdomen
Drug Interactions
- HMG-CoA reductase inhibitors (statins)Low
- Concurrent use of other antibioticsModerate
Population Constraints
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trials conducted; not approved by EMA
- United StatesInvestigationalInvestigational New Drug (IND) filed; no FDA approval
- United KingdomInvestigationalNo MHRA approval; development discontinued
No regulatory approval; development discontinued after Phase 2 trials.
Evidence & Sources
- Journal ArticleModerateEndres BT, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleModerateBoyanova L, Markovska R, Mitov I2019-01-01T00:00:00.000000Z
- Journal ArticleModerateKnight-Connoni V, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleHighKravets AM, Hanneke R, Nelson RL2023-01-01T00:00:00.000000Z
- Journal ArticleModerateChilton CH, Pickering DS, Freeman J2018-01-01T00:00:00.000000Z
- Journal ArticleHighMuhammad A, et al.2019-01-01T00:00:00.000000Z
Frequently Asked Questions
How does surotomycin differ from vancomycin in treating CDI?
Surotomycin targets the bacterial cell membrane and has limited activity against non‑Clostridioides gut microbes, whereas vancomycin is a broader‑spectrum agent. Clinical trials show comparable cure rates, but surotomycin may reduce recurrence of certain hypervirulent strains.
Is surotomycin approved for clinical use?
No. Surotomycin remains an investigational drug under clinical evaluation and has not received regulatory approval for any indication.
What is known about the safety of surotomycin?
Phase‑2 data indicate it is generally well tolerated with no major safety concerns reported. Because it is poorly absorbed, systemic adverse effects are expected to be minimal, but detailed safety data are limited.
Why might surotomycin preserve the gut microbiome better than other antibiotics?
In vitro and early‑clinical data suggest surotomycin lacks activity against Gram‑negative anaerobes and facultative anaerobes, limiting collateral damage to the normal microbial community while still killing C. difficile.
What dosage has been studied for surotomycin?
Clinical trials have used a 250 mg oral dose taken twice daily for ten days. This regimen achieves high colonic concentrations due to the drug’s low systemic absorption.
What is Surotomycin used for?
Surotomycin is educationally associated with: Prevention of CDI recurrence, Clostridioides difficile infection, Treatment of Clostridioides difficile infection. Educational only — not medical advice.
How is Surotomycin administered?
Recorded routes of administration: Oral.
What are the potential side effects of Surotomycin?
Reported adverse effects include: Headache, Nausea, Vomiting, Diarrhea (non‑C. difficile), Diarrhea, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Surotomycin?
Recorded contraindications: Known hypersensitivity to surotomycin or related lipopeptides, Hypersensitivity to surotomycin or related lipodepsipeptides. Consult a qualified clinician before use.